These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83. Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy. Liu Z; Li X; Gao Y; Liu J; Feng Y; Liu Y; Wang J; Wang C; Wang D; He J; Han W; Mei Q; Sun Y Mol Cancer; 2023 May; 22(1):84. PubMed ID: 37189103 [TBL] [Abstract][Full Text] [Related]
84. CAR T-cells targeting FLT3 have potent activity against FLT3 Jetani H; Garcia-Cadenas I; Nerreter T; Thomas S; Rydzek J; Meijide JB; Bonig H; Herr W; Sierra J; Einsele H; Hudecek M Leukemia; 2018 May; 32(5):1168-1179. PubMed ID: 29472720 [TBL] [Abstract][Full Text] [Related]
87. Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects. Ureshino H; Kurahashi Y; Watanabe T; Yamashita S; Kamachi K; Yamamoto Y; Fukuda-Kurahashi Y; Yoshida-Sakai N; Hattori N; Hayashi Y; Kawaguchi A; Tohyama K; Okada S; Harada H; Ushijima T; Kimura S Mol Cancer Ther; 2021 Aug; 20(8):1412-1421. PubMed ID: 34045225 [TBL] [Abstract][Full Text] [Related]
88. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies. Collinson-Pautz MR; Chang WC; Lu A; Khalil M; Crisostomo JW; Lin PY; Mahendravada A; Shinners NP; Brandt ME; Zhang M; Duong M; Bayle JH; Slawin KM; Spencer DM; Foster AE Leukemia; 2019 Sep; 33(9):2195-2207. PubMed ID: 30816327 [TBL] [Abstract][Full Text] [Related]
89. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115 [TBL] [Abstract][Full Text] [Related]
90. Acute myeloid leukemia immune escape by epigenetic CD48 silencing. Wang Z; Xiao Y; Guan W; Wang M; Chen J; Zhang L; Li Y; Xiong Q; Wang H; Wang M; Li Y; Lv N; Li Y; Wang L; Yu L Clin Sci (Lond); 2020 Jan; 134(2):261-271. PubMed ID: 31922199 [TBL] [Abstract][Full Text] [Related]
91. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells. Wang Y; Xu Y; Li S; Liu J; Xing Y; Xing H; Tian Z; Tang K; Rao Q; Wang M; Wang J J Hematol Oncol; 2018 May; 11(1):60. PubMed ID: 29716633 [TBL] [Abstract][Full Text] [Related]
92. Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. Yan B; Chen Q; Shimada K; Tang M; Li H; Gurumurthy A; Khoury JD; Xu B; Huang S; Qiu Y Leukemia; 2019 Apr; 33(4):931-944. PubMed ID: 30291336 [TBL] [Abstract][Full Text] [Related]
93. Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL. Zheng W; Wei J; Zebley CC; Jones LL; Dhungana Y; Wang YD; Mavuluri J; Long L; Fan Y; Youngblood B; Chi H; Geiger TL Blood; 2021 Jul; 138(2):122-135. PubMed ID: 33690816 [TBL] [Abstract][Full Text] [Related]
94. Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy. Minagawa K; Al-Obaidi M; Di Stasi A Methods Mol Biol; 2019; 1895():57-73. PubMed ID: 30539529 [TBL] [Abstract][Full Text] [Related]
95. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy. Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445 [TBL] [Abstract][Full Text] [Related]
96. Digging deep into "dirty" drugs - modulation of the methylation machinery. Pleyer L; Greil R Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693 [TBL] [Abstract][Full Text] [Related]
97. Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. Ataca Atilla P; McKenna MK; Tashiro H; Srinivasan M; Mo F; Watanabe N; Simons BW; McLean Stevens A; Redell MS; Heslop HE; Mamonkin M; Brenner MK; Atilla E J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32938629 [TBL] [Abstract][Full Text] [Related]
98. DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer. Terracina KP; Graham LJ; Payne KK; Manjili MH; Baek A; Damle SR; Bear HD Cancer Immunol Immunother; 2016 Sep; 65(9):1061-73. PubMed ID: 27416831 [TBL] [Abstract][Full Text] [Related]